Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1529307

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1529307

Asia Pacific T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Country and Growth Forecast, 2024 - 2031

PUBLISHED:
PAGES: 94 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Multi User License)
USD 1800
PDF (Corporate User License)
USD 2520

Add to Cart

The Asia Pacific T-cell Lymphoma Market would witness market growth of 9.1% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific T-cell Lymphoma Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $276.6 million by 2031. The Japan market is registering a CAGR of 8.4% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 9.8% during (2024 - 2031).

Multidisciplinary supportive care teams address patient needs, including pain management, nutritional support, psychosocial counseling, and symptom control, to improve quality of life. Evaluating novel agents, combination therapies, and treatment modalities is essential for these lymphoma patients to enhance outcomes and broaden therapeutic options. Participation in clinical trials is essential for this purpose.

Adopting and utilizing strategies for managing these lymphomas in healthcare settings are crucial aspects that influence patient outcomes, treatment efficacy, and overall healthcare delivery. Clinical trial data demonstrating efficacy, safety profiles, and comparative effectiveness against existing standards of care often guide the adoption of new treatments in these lymphomas. Consensus guidelines from professional organizations help standardize treatment protocols and support adoption decisions.

The growth of the hospital sector in India leads to the establishment of specialized oncology departments and comprehensive cancer centers across the country. These facilities offer state-of-the-art diagnostic capabilities and multidisciplinary treatment options for these lymphomas, including medical oncology, radiation oncology, and stem cell transplantation. As per the Investment Promotion and Facilitation Agency, in FY21, the hospital sector in India recorded revenue of INR 7940.87 billion and is projected to grow to INR 18,348.78 billion by FY27. Presently, the diagnostics sector in India is assessed to be worth $4 billion. The organized sector occupies almost 25% of this segment (15% in laboratories and 10% in radiology). The expansion of the hospital sector facilitates increased access to innovative therapies for these lymphomas in India. This includes the availability of targeted therapies, immunotherapies, and participation in clinical trials investigating novel treatment approaches that can potentially enhance treatment outcomes and patient survival rates. In conclusion, rising hospital sector and high rates of the non-Hodgkin lymphoma is driving the growth of the market.

Based on Type, the market is segmented into Peripheral (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Others) and Lymphoblastic. Based on Therapy, the market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd
  • Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc.
  • Genor Biopharma Co. Ltd.
  • Innate Pharma SA
  • Dizal Pharmaceutical Co. Ltd.

Asia Pacific T-cell Lymphoma Market Report Segmentation

By Type

  • Peripheral
    • Cutaneous T-cell Lymphoma
    • Anaplastic Large Cell Lymphoma
    • Angio-immuno-blastic T-cell Lymphoma
    • Others
  • Lymphoblastic

By Therapy

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific T-cell Lymphoma Market, by Type
    • 1.4.2 Asia Pacific T-cell Lymphoma Market, by Therapy
    • 1.4.3 Asia Pacific T-cell Lymphoma Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
    • 3.2.3 Market Opportunities
    • 3.2.4 Market Challenges
  • 3.3 Porter Five Forces Analysis

Chapter 4. Asia Pacific T-cell Lymphoma Market by Type

  • 4.1 Asia Pacific Peripheral Market by Country
  • 4.2 Asia Pacific T-cell Lymphoma Market by Peripheral Type
    • 4.2.1 Asia Pacific Cutaneous T-cell Lymphoma Market by Country
    • 4.2.2 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country
    • 4.2.3 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country
    • 4.2.4 Asia Pacific Others Market by Country
  • 4.3 Asia Pacific Lymphoblastic Market by Country

Chapter 5. Asia Pacific T-cell Lymphoma Market by Therapy

  • 5.1 Asia Pacific Chemotherapy Market by Country
  • 5.2 Asia Pacific Radiotherapy Market by Country
  • 5.3 Asia Pacific Immunotherapy Market by Country
  • 5.4 Asia Pacific Stem Cell Transplantation Market by Country
  • 5.5 Asia Pacific Others Market by Country

Chapter 6. Asia Pacific T-cell Lymphoma Market by Country

  • 6.1 China T-cell Lymphoma Market
    • 6.1.1 China T-cell Lymphoma Market by Type
      • 6.1.1.1 China T-cell Lymphoma Market by Peripheral Type
    • 6.1.2 China T-cell Lymphoma Market by Therapy
  • 6.2 Japan T-cell Lymphoma Market
    • 6.2.1 Japan T-cell Lymphoma Market by Type
      • 6.2.1.1 Japan T-cell Lymphoma Market by Peripheral Type
    • 6.2.2 Japan T-cell Lymphoma Market by Therapy
  • 6.3 India T-cell Lymphoma Market
    • 6.3.1 India T-cell Lymphoma Market by Type
      • 6.3.1.1 India T-cell Lymphoma Market by Peripheral Type
    • 6.3.2 India T-cell Lymphoma Market by Therapy
  • 6.4 South Korea T-cell Lymphoma Market
    • 6.4.1 South Korea T-cell Lymphoma Market by Type
      • 6.4.1.1 South Korea T-cell Lymphoma Market by Peripheral Type
    • 6.4.2 South Korea T-cell Lymphoma Market by Therapy
  • 6.5 Singapore T-cell Lymphoma Market
    • 6.5.1 Singapore T-cell Lymphoma Market by Type
      • 6.5.1.1 Singapore T-cell Lymphoma Market by Peripheral Type
    • 6.5.2 Singapore T-cell Lymphoma Market by Therapy
  • 6.6 Malaysia T-cell Lymphoma Market
    • 6.6.1 Malaysia T-cell Lymphoma Market by Type
      • 6.6.1.1 Malaysia T-cell Lymphoma Market by Peripheral Type
    • 6.6.2 Malaysia T-cell Lymphoma Market by Therapy
  • 6.7 Rest of Asia Pacific T-cell Lymphoma Market
    • 6.7.1 Rest of Asia Pacific T-cell Lymphoma Market by Type
      • 6.7.1.1 Rest of Asia Pacific T-cell Lymphoma Market by Peripheral Type
    • 6.7.2 Rest of Asia Pacific T-cell Lymphoma Market by Therapy

Chapter 7. Company Profiles

  • 7.1 Bristol Myers Squibb Company
    • 7.1.1 Company Overview
    • 7.1.2 SWOT Analysis
  • 7.2 Daiichi Sankyo Company, Limited
    • 7.2.1 Company Overview
    • 7.2.2 SWOT Analysis
  • 7.3 Eisai Co., Ltd.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.5 SWOT Analysis
  • 7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
    • 7.4.1 Company Overview
  • 7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
    • 7.5.1 Company Overview
  • 7.6 Citius Pharmaceuticals, Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Recent strategies and developments:
      • 7.6.2.1 Trials and Approvals:
  • 7.7 Genor Biopharma Co. Ltd
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expenses
  • 7.8 Innate Pharma SA
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Research & Development Expenses
  • 7.9 Dizal Pharmaceutical Co. Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Trials and Approvals:

LIST OF TABLES

  • TABLE 1 Asia Pacific T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 2 Asia Pacific T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 3 Asia Pacific T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 4 Asia Pacific T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 5 Asia Pacific Peripheral Market by Country, 2020 - 2023, USD Million
  • TABLE 6 Asia Pacific Peripheral Market by Country, 2024 - 2031, USD Million
  • TABLE 7 Asia Pacific T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 8 Asia Pacific T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 9 Asia Pacific Cutaneous T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 10 Asia Pacific Cutaneous T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 11 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 12 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 13 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 14 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 15 Asia Pacific Others Market by Country, 2020 - 2023, USD Million
  • TABLE 16 Asia Pacific Others Market by Country, 2024 - 2031, USD Million
  • TABLE 17 Asia Pacific Lymphoblastic Market by Country, 2020 - 2023, USD Million
  • TABLE 18 Asia Pacific Lymphoblastic Market by Country, 2024 - 2031, USD Million
  • TABLE 19 Asia Pacific T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 20 Asia Pacific T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 21 Asia Pacific Chemotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 22 Asia Pacific Chemotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 23 Asia Pacific Radiotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 24 Asia Pacific Radiotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 25 Asia Pacific Immunotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 26 Asia Pacific Immunotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 27 Asia Pacific Stem Cell Transplantation Market by Country, 2020 - 2023, USD Million
  • TABLE 28 Asia Pacific Stem Cell Transplantation Market by Country, 2024 - 2031, USD Million
  • TABLE 29 Asia Pacific Others Market by Country, 2020 - 2023, USD Million
  • TABLE 30 Asia Pacific Others Market by Country, 2024 - 2031, USD Million
  • TABLE 31 Asia Pacific T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 32 Asia Pacific T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 33 China T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 34 China T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 35 China T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 36 China T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 37 China T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 38 China T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 39 China T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 40 China T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 41 Japan T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 42 Japan T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 43 Japan T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 44 Japan T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 45 Japan T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 46 Japan T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 47 Japan T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 48 Japan T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 49 India T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 50 India T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 51 India T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 52 India T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 53 India T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 54 India T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 55 India T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 56 India T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 57 South Korea T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 58 South Korea T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 59 South Korea T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 60 South Korea T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 61 South Korea T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 62 South Korea T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 63 South Korea T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 64 South Korea T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 65 Singapore T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 66 Singapore T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 67 Singapore T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 68 Singapore T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 69 Singapore T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 70 Singapore T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 71 Singapore T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 72 Singapore T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 73 Malaysia T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 74 Malaysia T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 75 Malaysia T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 76 Malaysia T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 77 Malaysia T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 78 Malaysia T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 79 Malaysia T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 80 Malaysia T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 81 Rest of Asia Pacific T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 82 Rest of Asia Pacific T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 83 Rest of Asia Pacific T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 84 Rest of Asia Pacific T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 85 Rest of Asia Pacific T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 86 Rest of Asia Pacific T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 87 Rest of Asia Pacific T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 88 Rest of Asia Pacific T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 89 Key Information - Bristol Myers Squibb Company
  • TABLE 90 Key Information - Daiichi Sankyo Company, Limited
  • TABLE 91 Key Information - Eisai Co., Ltd.
  • TABLE 92 Key Information - Acrotech Biopharma Inc.
  • TABLE 93 Key Information - Shenzhen Chipscreen Biosciences Co., Ltd.
  • TABLE 94 Key Information - Citius Pharmaceuticals, Inc.
  • TABLE 95 Key Information - Genor Biopharma Co. Ltd
  • TABLE 96 Key Information - Innate Pharma SA
  • TABLE 97 Key Information - Dizal Pharmaceutical Co. Ltd.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!